News | November 11, 2021
Hester Biosciences to acquire 50 % stake in Thrishool Exim, Tanzania
The consideration for the acquisition is US $ 2.25 million
The consideration for the acquisition is US $ 2.25 million
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Expertise in exosomes isolation and characterization will drive innovation in this field
The NFI is published to promote the rational use of medicines in the country.
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Subscribe To Our Newsletter & Stay Updated
